Regulus Therapeutics Announces First Patient Dosed in Phase 1b Clinical Trial of RGLS4326 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
- Thursday, October 15, 2020, 7:16
- Business
- Add a comment
LA JOLLA, Calif., Oct. 15, 2020 /PRNewswire/ — Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs (the “Company” or “Regulus”), today announced initiation of dosing in its Phase 1b…
About the Author
adminasapcorp has written 42188 stories on this site.